|drug174||Blood plasma Wiki||1.00|
|drug193||CAG length <24 Wiki||1.00|
|drug194||CAG length >=24 Wiki||1.00|
There is one clinical trial.
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess the risk of developing severe symptoms following COVID-19 infection, The COVID-19 Androgen Sensitivity Test requires a health care professional to collect a DNA sample using an FDA cleared DNA sample collection kit.
Description: Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.Measure: Hospital-free days to Day 28 [ Time Frame: 28 days] Time: 28 days
Description: Defined as discharged, hospitalization, admission to intensive care unit [ICU] and deathMeasure: 1. Severity of Disease Time: Day 28